KDR Activating Mutations in Human Angiosarcomas Are Sensitive to Specific Kinase Inhibitors
Population
Human angiosarcoma samples and COS-7 cells transfected with KDR mutants
Design
Preclinical
Authors
Discussion
Loading...
Member takes
Implication
KDR inhibition merits clinical exploration in angiosarcoma; leaves open prospective validation of efficacy and safety.
Structured PICO
P
Population
Human angiosarcoma samples and COS-7 cells transfected with KDR mutants
I
Intervention
Specific KDR inhibitors
O
Outcome
Ligand-independent activation of the kinase and its inhibitionsurrogate
Identification of KDR activating mutations in 10% of angiosarcomas provides a mechanistic basis for using VEGFR-directed therapies in these patients.
Cite This Study
Antonescu et al. (2009) studied this question.